Table 2.
Stage of remission, therapy and metastases at study entry
|
All patients |
Group I: lung cancer |
Group II: breast cancer |
Group III: GI tumors |
Group IV: hematol. |
Group V: uro-genital |
Group VI: CUP |
Group VII: others |
|
|---|---|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
|
Stage of remission | ||||||||
| ID |
99 (65.6) |
27 (27.3) |
1 (1.1) |
9 (9.1) |
45 (45.5) |
5 (5) |
5 (5) |
7 (7) |
| CR |
2 (1.3) |
0 |
0 |
0 |
2 (100) |
0 |
0 |
0 |
| PR |
4 (2.6) |
1 (25) |
0 |
0 |
2 (50) |
1(25) |
0 |
0 |
| NC |
2 (1.3) |
1 (50) |
0 |
0 |
1 (50) |
0 |
0 |
0 |
| PD |
44 (29.1) |
8 (18.2) |
9 (20.5) |
7 (15.9) |
12 (27.3) |
2 (4.5) |
0 |
6 (13.6) |
|
Metastases | ||||||||
| CNS |
16 (10.6) |
8 (50) |
0 |
1 (6.3) |
3 (18.7) |
2 (12.5) |
0 |
2 (12.5) |
| Bone |
32 (21.2) |
9 (45) |
6 (18.8) |
1 (3.1) |
8 (25) |
3 (9.4) |
2 (6.3) |
3 (9.4) |
| Liver |
17 (11.3) |
2 (11.8) |
2 (11.8) |
8 (47.0) |
3 (17.6) |
2 (11.8) |
0 |
0 |
| Lymphatic |
85 (56.3) |
21 (24.1) |
7 (8) |
11 (12.6) |
33 (37.9) |
5 (5.7) |
3 (3.4) |
5 (5.7) |
|
Therapy (at study entry) | ||||||||
| Chemo |
18 (11.9) |
4 (22.2) |
1 (5.6) |
1 (5.6) |
4 (22.2) |
2 (11.1) |
1 (5.6) |
5 (27.7) |
| Radiation |
3 (2) |
2 (66.7) |
0 |
0 |
0 |
0 |
0 |
1 (33.3) |
| Hormone | 3 (2) | 0 | 1 (33.3) | 0 | 2 (66.7) | 0 | 0 | 0 |
ID, initial diagnosis; CR, complete remission; PR, partial remission; NC, no change; PD, progressive disease.